Plain-language summary
Extracellular vesicles are attractive carriers for inhaled lung therapy, but nebulisation shears them apart at the air-liquid interface. This group fused EVs with liposomes to make a hybrid vesicle and loaded it with nintedanib for pulmonary fibrosis. Screening the composition showed a trade-off between retained EV biological function and aerosol robustness, with an EV protein to lipid mass ratio of 3 to 7 giving the best balance: better mucus penetration and cell association, less size drift after nebulisation, and a preserved aerodynamic profile. Density-gradient fractionation and physical-mixture controls supported genuine hybrid particles rather than a simple mixture, and a FRET proximity assay indicated greater resistance to aerosol-induced membrane perturbation. In mice the formulation prolonged pulmonary retention and attenuated bleomycin-induced fibrosis, with reduced fibroblast activation.
Key findings
- EVs were fused with liposomes to create lipid-protein hybrid vesicles engineered to survive nebulisation shear.
- The hybrid was loaded with nintedanib, a drug already used for pulmonary fibrosis, as an inhalable formulation.
- An EV protein to lipid mass ratio of 3 to 7 balanced retained EV functionality against aerosol robustness.
- At that ratio the formulation penetrated mucus better, drifted less in size after nebulisation, and kept its aerodynamic profile.
- Fractionation and physical-mixture controls indicated genuine hybrid particles rather than coexisting EVs and liposomes.
- In mice the formulation prolonged lung retention and attenuated bleomycin-induced fibrosis with reduced fibroblast activation. The work is preclinical.
Why this matters for lung repair
This is the closest paper in the current batch to the engineering problem that inhaled vesicle therapy has to solve: keeping a biological membrane intact through a nebuliser. The reported trade-off between EV function and aerosol stability, and the composition ratio that balances them, is the kind of design rule the field needs. It also provides a mouse-model readout for prolonged pulmonary retention. The findings are preclinical and describe a drug-loaded formulation, not JuvGuard's product.
Original abstract
Extracellular vesicles (EVs) are promising biomimetic nanocarriers for pulmonary delivery, but their inhalation translation is limited by membrane fragility under aerosol-induced shear and air-liquid interfacial stress. Here, we developed an EV-liposome hybrid vesicle formulation (NIN@SV) for inhalable delivery of nintedanib and identified a composition-dependent balance between EV-derived biological functionality and aerosol robustness. An optimized EV protein:NIN@LP lipid mass ratio of 3:7 enhanced mucus penetration and cellular association while minimizing post-nebulization size drift and preserving aerodynamic performance. Density-gradient fractionation and physical-mixture controls supported the formation of a hybrid vesicle-enriched population rather than simple coexistence of unfused EVs and liposomes. In parallel, FRET-assisted membrane-proximity analysis, calibrated using disruption controls, indicated improved resistance of NIN@SV to aerosol-induced membrane perturbation. Functionally, NIN@SV enhanced formulation-associated cellular association, prolonged pulmonary retention, and attenuated bleomycin-induced pulmonary fibrosis under the tested nominal inhaled dosing regimen. Mechanistically, NIN@SV suppressed fibroblast activation and attenuated pro-fibrotic macrophage-associated features. Together, these findings support an aerosol-resilient EV-liposome membrane-engineering strategy and provide a practical design rationale for inhalable hybrid vesicles in pulmonary drug delivery.
Frequently asked questions
What did this study find?
Extracellular vesicles are attractive carriers for inhaled lung therapy, but nebulisation shears them apart at the air-liquid interface. This group fused EVs with liposomes to make a hybrid vesicle and loaded it with nintedanib for pulmonary fibrosis. Screening the composition showed a trade-off between retained EV biological function and aerosol robustness, with an EV protein to lipid mass ratio of 3 to 7 giving the best balance: better mucus penetration and cell association, less size drift after nebulisation, and a preserved aerodynamic profile. Density-gradient fractionation and physical-mixture controls supported genuine hybrid particles rather than a simple mixture, and a FRET proximity assay indicated greater resistance to aerosol-induced membrane perturbation. In mice the formulation prolonged pulmonary retention and attenuated bleomycin-induced fibrosis, with reduced fibroblast activation.
Was this tested in humans or in the laboratory?
This is delivery-science work, focused on how the vesicles behave when they are administered.
Where can I read the original paper?
The full text lives with the publisher: https://doi.org/10.1002/adhm.71647
Does this study prove that JuvGuard works?
No. This is an independent, peer-reviewed study on extracellular vesicles. JuvGuard references the published literature for education only. A single paper cannot establish that any product works, and nothing here is medical advice.
How to cite this paper
Yan Xin, Zhang Qi, Xu Jing, Qi Hengkai, Bian Jing, Zhao Honglian et al.. Engineering Aerosol-Resilient EV-Liposome Hybrid Vesicles for Inhalable Nintedanib Delivery in Pulmonary Fibrosis.. Advanced healthcare materials. 2026, 2026-08-27. DOI: 10.1002/adhm.71647
Source & verification
- Journal: Advanced healthcare materials
- Published: 27 August 2026
- DOI: 10.1002/adhm.71647
- PubMed ID: 42657629
- Indexed via: pubmed
- MeSH terms: Indoles, Liposomes, Animals, Aerosols, Pulmonary Fibrosis, Administration, Inhalation, Mice, Extracellular Vesicles, Mice, Inbred C57BL, Humans, Bleomycin